Immunotherapy in Gastric Cancer von Högner, Anica, Moehler, Markus

Volltext

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer von Kelly, Ronan J, Ajani, Jaffer A, Kuzdzal, Jaroslaw, Zander, Thomas, Van Cutsem, Eric, Piessen, Guillaume, Mendez, Guillermo, Feliciano, Josephine, Motoyama, Satoru, Lièvre, Astrid, Uronis, Hope, Elimova, Elena, Grootscholten, Cecile, Geboes, Karen, Zafar, Syed, Snow, Stephanie, Ko, Andrew H, Feeney, Kynan, Schenker, Michael, Kocon, Piotr, Zhang, Jenny, Zhu, Lili, Lei, Ming, Singh, Prianka, Kondo, Kaoru, Cleary, James M, Moehler, Markus

Volltext

Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer von Bang, Yung-Jue, Cho, Jae Yong, Kim, Yeul Hong, Kim, Jin Won, Di Bartolomeo, Maria, Ajani, Jaffer A, Yamaguchi, Kensei, Balogh, Agnes, Sanchez, Teresa, Moehler, Markus

Volltext

Late-line treatment in metastatic gastric cancer: today and tomorrow von Smyth, Elizabeth C., Moehler, Markus

Volltext

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer von Shitara, Kohei, Ajani, Jaffer A., Moehler, Markus, Garrido, Marcelo, Gallardo, Carlos, Shen, Lin, Yamaguchi, Kensei, Wyrwicz, Lucjan, Skoczylas, Tomasz, Bragagnoli, Arinilda Campos, Liu, Tianshu, Tehfe, Mustapha, Elimova, Elena, Bruges, Ricardo, Zander, Thomas, de Azevedo, Sergio, Kowalyszyn, Ruben, Pazo-Cid, Roberto, Schenker, Michael, Cleary, James M., Yanez, Patricio, Feeney, Kynan, Karamouzis, Michalis V., Poulart, Valerie, Lei, Ming, Xiao, Hong, Kondo, Kaoru, Li, Mingshun, Janjigian, Yelena Y.

Volltext

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this... von Stintzing, Sebastian, Dr, Modest, Dominik P, MD, Rossius, Lisa, Lerch, Markus M, Prof, von Weikersthal, Ludwig Fischer, MD, Decker, Thomas, MD, Kiani, Alexander, MD, Vehling-Kaiser, Ursula, MD, Al-Batran, Salah-Eddin, Prof, Heintges, Tobias, MD, Lerchenmüller, Christian, MD, Kahl, Christoph, MD, Seipelt, Gernot, MD, Kullmann, Frank, MD, Stauch, Martina, MD, Scheithauer, Werner, Prof, Held, Swantje, MSc, Giessen-Jung, Clemens, MD, Moehler, Markus, Prof, Jagenburg, Andreas, MD, Kirchner, Thomas, Prof, Jung, Andreas, Prof, Heinemann, Volker, Prof

Volltext

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial von Heinemann, Volker, von Weikersthal, Ludwig Fischer, Decker, Thomas, Kiani, Alexander, Kaiser, Florian, Al-Batran, Salah-Edin, Heintges, Tobias, Lerchenmüller, Christoph, Kahl, Christoph, Seipelt, Gernot, Kullmann, Frank, Moehler, Markus, Scheithauer, Werner, Held, Swantje, Miller-Phillips, Lisa, Modest, Dominik Paul, Jung, Andreas, Kirchner, Thomas, Stintzing, Sebastian

Volltext

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial von Heinemann, Volker, Prof, von Weikersthal, Ludwig Fischer, MD, Decker, Thomas, MD, Kiani, Alexander, Prof, Vehling-Kaiser, Ursula, MD, Al-Batran, Salah-Eddin, Prof, Heintges, Tobias, Prof, Lerchenmüller, Christian, MD, Kahl, Christoph, MD, Seipelt, Gernot, MD, Kullmann, Frank, Prof, Stauch, Martina, MD, Scheithauer, Werner, Prof, Hielscher, Jörg, Scholz, Michael, MD, Müller, Sebastian, MD, Link, Hartmut, Prof, Niederle, Norbert, Prof, Rost, Andreas, MD, Höffkes, Heinz-Gert, Prof, Moehler, Markus, Prof, Lindig, Reinhard U, MD, Modest, Dominik P, MD, Rossius, Lisa, MD, Kirchner, Thomas, Prof, Jung, Andreas, PhD, Stintzing, Sebastian, MD

Volltext

Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists von Stein, Alexander, Moehler, Markus, Trojan, Jörg, Goekkurt, Eray, Vogel, Arndt

Volltext

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial von Lordick, Florian, Prof, Kang, Yoon-Koo, Prof, Chung, Hyun-Cheol, Prof, Salman, Pamela, MD, Oh, Sang Cheul, Prof, Bodoky, György, Prof, Kurteva, Galina, MD, Volovat, Constantin, MD, Moiseyenko, Vladimir M, Prof, Gorbunova, Vera, Prof, Park, Joon Oh, MD, Sawaki, Akira, MD, Celik, Ilhan, Prof, Götte, Heiko, PhD, Melezínková, Helena, MD, Moehler, Markus, Prof

Volltext

MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma von Catenacci, Daniel V. T., Rosales, Minori, Chung, Hyun Cheol, Yoon, Harry H., Shen, Lin, Moehler, Markus, Kang, Yoon-Koo

Volltext

Molecular landscape of esophageal cancer: implications for early detection and personalized therapy von Talukdar, Fazlur Rahman, di Pietro, Massimiliano, Secrier, Maria, Moehler, Markus, Goepfert, Katrin, Lima, Sheila Soares Coelho, Pinto, Luis Felipe Ribeiro, Hendricks, Denver, Parker, Mohamed Iqbal, Herceg, Zdenko

Volltext

Comparative analysis of nuclear and mitochondrial DNA from tissue and liquid biopsies of colorectal cancer patients von Haupts, Anna, Vogel, Anne, Foersch, Sebastian, Hartmann, Monika, Maderer, Annett, Wachter, Nicolas, Huber, Tobias, Kneist, Werner, Roth, Wilfried, Lang, Hauke, Moehler, Markus, Hartmann, Nils

Volltext

Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives von Taieb, Julien, Moehler, Markus, Boku, Narikazu, Ajani, Jaffer A., Yañez Ruiz, Eduardo, Ryu, Min-Hee, Guenther, Silke, Chand, Vikram, Bang, Yung-Jue

Volltext

Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial von Hofheinz, Ralf-Dieter, Prof, Wenz, Frederik, Prof, Post, Stefan, Prof, Matzdorff, Axel, Prof, Laechelt, Stephan, MD, Hartmann, Jörg T, Prof, Müller, Lothar, MD, Link, Hartmut, Prof, Moehler, Markus, Prof, Kettner, Erika, MD, Fritz, Elisabeth, MD, Hieber, Udo, MD, Lindemann, Hans Walter, MD, Grunewald, Martina, MD, Kremers, Stephan, MD, Constantin, Christian, MD, Hipp, Matthias, MD, Hartung, Gernot, Prof, Gencer, Deniz, MD, Kienle, Peter, Prof, Burkholder, Iris, PhD, Hochhaus, Andreas, Prof

Volltext

Elevated serum levels of methylglyoxal are associated with impaired liver function in patients with liver cirrhosis von Michel, Maurice, Hess, Cornelius, Kaps, Leonard, Kremer, Wolfgang M., Hilscher, Max, Galle, Peter R., Moehler, Markus, Schattenberg, Jörn M., Wörns, Marcus-Alexander, Labenz, Christian, Nagel, Michael

Volltext

VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence... von Smyth, Elizabeth, Knoedler, Maren, Giraut, Anne, Mauer, Murielle, Nilsson, Magnus, Van Grieken, Nicole, Wagner, Anna Dorothea, Moehler, Markus, Lordick, Florian

Volltext

PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression von Dörsam, Bastian, Seiwert, Nina, Foersch, Sebastian, Stroh, Svenja, Nagel, Georg, Begaliew, Diana, Diehl, Erika, Kraus, Alexander, McKeague, Maureen, Minneker, Vera, Roukos, Vassilis, Reißig, Sonja, Waisman, Ari, Moehler, Markus, Stier, Anna, Mangerich, Aswin, Dantzer, Françoise, Kaina, Bernd, Fahrer, Jörg

Volltext

High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells von Schimanski, Carl Christoph, Frerichs, Kirsten, Rahman, Fareed, Berger, Martin, Lang, Hauke, Galle, Peter R, Moehler, Markus, Gockel, Ines

Volltext

Young-onset gastric cancer and Epstein-Barr Virus (EBV) - a major player in the pathogenesis? von Moore, Assaf, Hikri, Elad, Goshen-Lago, Tal, Barkan, Tamar, Morgenstern, Sara, Brook, Elena, Maderer, Annett, Roth, Wilfried, Gordon, Noa, Kashtan, Hanoch, Brenner, Baruch, Moehler, Markus, Aharon, Irit Ben

Volltext